Campbell & Co Investment Adviser’s Ligand Pharmaceuticals LGND Stock Holding History

Campbell & Co Investment Adviser’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,690	Closed	-$369K	–	1220
2024 Q3	$369K	Hold	3,690	–	–	0.03%	827
2024 Q2	$311K	Sell	3,690 -1,071	-22%	-$85.2K	0.03%	818
2024 Q1	$348K	Sell	4,761 -2,820	-37%	-$208K	0.03%	847
2023 Q4	$541K	Buy	7,581 +2,435	+47%	+$144K	0.05%	670
2023 Q3	$308K	Buy	5,146 +618	+14%	+$40.7K	0.04%	704
2023 Q2	$326K	Buy	4,528 +151	+3%	+$11.3K	0.06%	627
2023 Q1	$322K	Sell	4,377 -797	-15%	-$56.7K	0.06%	579
2022 Q4	$346K	Buy	+5,174	New	+$336K	0.08%	485
2019 Q1	–	Sell	-2,462	Closed	-$231K	–	563
2018 Q4	$231K	Buy	+2,462	New	+$262K	0.23%	249
2018 Q2	–	Sell	-2,723	Closed	-$281K	–	459
2018 Q1	$281K	Buy	+2,723	New	+$269K	0.24%	184

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Campbell & Co Investment Adviser's LGND Position: Q4 2024 in Review

Campbell & Co Investment Adviser sold out of Ligand Pharmaceuticals (LGND) in Q4 2024, closing a stake of 3,690 shares — an estimated $369K sold.

Campbell & Co Investment Adviser first reported a position in LGND in Q1 2018 and held it in 10 quarters. The position peaked at $541K in Q4 2023. 258 funds tracked by Wall St. Rank hold LGND as of Q4 2024.

Campbell & Co Investment Adviser reported no remaining Ligand Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Campbell & Co Investment Adviser sold 3,690 Ligand Pharmaceuticals shares in Q4 2024, an estimated $369K.
Campbell & Co Investment Adviser first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 10 quarters.
Campbell & Co Investment Adviser's Ligand Pharmaceuticals position peaked at $541K in Q4 2023.
258 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2024, filed 10 Feb 2025.